

*The American Journal of Psychiatry* requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:

- Robert Freedman, M.D., reports no financial relationships with commercial interests.
- David A. Lewis, M.D., received investigator-initiated research support from the BMS Foundation, Bristol-Myers Squibb, Curridium Ltd., and Pfizer. He has served as a consultant in the areas of target identification and validation and new compound development to AstraZeneca, BioLine RX, Hoffman-Roche, Lilly, Merck, Neurogen, and SK Life Science.
- Robert Michels, M.D., reports no financial relationships with commercial interests.
- Daniel S. Pine, M.D., reports no financial relationships with commercial interests.
- Susan K. Schultz, M.D., has received research support from the Alzheimer's Disease Cooperative Study for a project conducted in partnership with Baxter Healthcare.
- Carol A. Tamminga, M.D., has served on advisory boards for Acadia Pharmaceuticals and Intracellular Therapies; has served as a consultant for Astellas, Cypress Bioscience, Eli Lilly, PureTech Ventures, and Sunovion; and served as an expert witness for Finnegan Henderson Farabow Garrett & Dunner, LLP.